Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update

Rhea-AI Summary

Editas Medicine, a clinical-stage genome editing company, will host a conference call and webcast on February 22, 2023, at 8:00 a.m. ET, to discuss its fourth quarter and full year 2022 results along with a corporate update. U.S. callers can join by dialing 877-407-0989 and international callers should dial 201-389-0921. The call can also be accessed via the Editas Medicine website in the 'Investors' section, with a replay available about an hour after the call ends.

Editas focuses on developing transformative genomic medicines utilizing CRISPR technologies, and holds exclusive licenses for crucial patents in human medicine.

CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 22, 2023, at 8:00 a.m. ET to discuss results for the fourth quarter and full year of 2022 and to provide a corporate update.

To access the conference call:

• U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.
• Participants should ask to be connected to the Editas Medicine Earnings Conference Call.
  

The conference call will also be webcast and can be accessed from the “Investors” section of the Editas Medicine website at https://www.editasmedicine.com. A replay will be available at the same site approximately one hour after the completion of the call.

About Editas Medicine
As a clinical stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Media Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investor Contact:
Ron Moldaver
(617) 401-9052
ir@editasmed.com

FAQ

What date will Editas Medicine hold its conference call for Q4 2022 results?

Editas Medicine will hold its conference call on February 22, 2023.

What time is the Editas Medicine conference call scheduled for?

The conference call is scheduled for 8:00 a.m. ET.

How can I access the Editas Medicine conference call?

You can access the call by dialing 877-407-0989 for U.S. callers or 201-389-0921 for international callers.

Where can I find the webcast for Editas Medicine's earnings call?

The webcast can be found in the 'Investors' section of the Editas Medicine website.

What focus does Editas Medicine have in the biotech industry?

Editas Medicine focuses on developing genome editing treatments using CRISPR technology for serious diseases.